Flubendazole elicits anti‐metastatic effects in triple‐negative breast cancer via STAT3 inhibition

Tumor metastasis remains the cause of 90% of cancer‐related deaths. Cancer stem cells (CSC) are thought to be responsible for the aggressive and metastatic nature of triple‐negative breast cancers (TNBC), and new therapeutic strategies are being devised to target them. Flubendazole (FLU) is a widely used anthelmintic agent that also exhibits anticancer activity in several cancer types. The aim of this study was to characterize the mechanism of action of FLU on breast cancer stem cell (BCSC)‐like properties and metastasis in TNBC. FLU treatment caused a significant induction of apoptosis, accompanied by G2/M phase accumulation, caspase‐3/‐7 activation and the dysregulation of STAT3 activation in TNBC cells. The latter phenomenon was associated with impairment of cancer stem‐like traits, concomitant with a reduction in the CD24low/CD44high, CD24high/CD49fhigh subpopulation, ALDH1 activity and mammosphere formation. The BCSC‐enriched populations exhibited enhanced metastasis with higher STAT3 activation, while FLU administration inhibited tumor growth, angiogenesis and lung and liver metastasis, coinciding with decreased MMP‐2 and MMP‐9 levels in circulating blood. FLU kills not only rapid proliferating tumor cells but also effectively eradicates BCSC‐like cells in vitro and in vivo. Our findings warrant further investigation of FLU as a treatment for metastatic TNBC.

[1]  Ji Young Kim,et al.  Inhibition of ubiquitin-specific protease 34 (USP34) induces epithelial-mesenchymal transition and promotes stemness in mammary epithelial cells. , 2017, Cellular signalling.

[2]  Ji Young Kim,et al.  Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells. , 2017, Biochemical and biophysical research communications.

[3]  E. Rudolf,et al.  Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy. , 2017, Acta medica.

[4]  Ji Young Kim,et al.  Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. , 2017, Cancer letters.

[5]  Jiayuh Lin,et al.  STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells , 2016, International journal of oncology.

[6]  M. Zhong,et al.  ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway , 2016, OncoTargets and therapy.

[7]  Ji Young Kim,et al.  Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer. , 2016, Cancer letters.

[8]  C. Ban,et al.  Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. , 2016, Biochimica et biophysica acta.

[9]  H. Resat,et al.  Constitutive activation of STAT3 in breast cancer cells: A review , 2016, International journal of cancer.

[10]  E. Rudolf,et al.  Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro , 2016, The Journal of pharmacy and pharmacology.

[11]  Sriganesh Srihari,et al.  Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. , 2015, Trends in pharmacological sciences.

[12]  Ji Young Kim,et al.  Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells , 2015, PloS one.

[13]  Manisha Singh,et al.  Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer , 2015, Scientific Reports.

[14]  J. McCaffrey,et al.  The fate of chemoresistance in triple negative breast cancer (TNBC) , 2015, BBA clinical.

[15]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[16]  M. Quinn,et al.  Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden , 2014, BMC Cancer.

[17]  Michael K. Wendt,et al.  STAT3 and epithelial–mesenchymal transitions in carcinomas , 2014, JAK-STAT.

[18]  M. Wicha,et al.  Evaluation of STAT3 Signaling in ALDH+ and ALDH+/CD44+/CD24− Subpopulations of Breast Cancer Cells , 2013, PloS one.

[19]  R. Gude,et al.  Role of STAT3 in Cancer Metastasis and Translational Advances , 2013, BioMed research international.

[20]  Ming Li,et al.  The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.

[21]  E. Tokunaga,et al.  Vimentin as a poor prognostic factor for triple-negative breast cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[22]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[23]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[24]  Georg Krupitza,et al.  Initial steps of metastasis: Cell invasion and endothelial transmigration , 2011, Mutation research.

[25]  André F. Vieira,et al.  Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype , 2011, Journal of Clinical Pathology.

[26]  S. Lakhani,et al.  Breast cancer stem cells: treatment resistance and therapeutic opportunities. , 2011, Carcinogenesis.

[27]  T. Geary,et al.  Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs , 2011, Expert review of anti-infective therapy.

[28]  S. Isakoff,et al.  Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents , 2010, Cancer journal.

[29]  C. Lanusse,et al.  Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. , 2009, Parasitology international.

[30]  M. Sukhai,et al.  The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. , 2009, Blood.

[31]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[32]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[33]  Ps Patel,et al.  Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. , 2009, Indian journal of cancer.

[34]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[35]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[36]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[38]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[39]  F. Ali-Osman,et al.  Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis , 2004, Oncogene.

[40]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[41]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[42]  J. Abbruzzese,et al.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.

[43]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[44]  L. Dufour,et al.  Treatment of neurocysticercosis with flubendazole. , 1984, The American journal of tropical medicine and hygiene.

[45]  D. Vuitton,et al.  [Treatment of human alveolar echinococcosis with flubendazole. Clinical, morphological and immunological study]. , 1984, Gastroenterologie clinique et biologique.

[46]  Ji Young Kim,et al.  Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer. , 2018, Cancer letters.

[47]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[48]  W. Janzen,et al.  High Throughput Screening , 2009, Methods in Molecular Biology.